An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.
作者信息
Steeg Patricia S, Anderson Robin L, Bar-Eli Menashe, Chambers Ann F, Eccles Suzanne A, Hunter Kent, Itoh Kazuyuki, Kang Yibin, Matrisian Lynn M, Sleeman Jonathan P, Theodorescu Dan, Thompson Erik W, Welch Danny R
机构信息
Metastasis Research Society Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.
Board Member, Metastasis Research Society Metastasis Research Laboratory, Peter MacCallum Cancer Centre Department of Pathology, The University of Melbourne Melbourne VIC Australia 8006.
出版信息
Clin Cancer Res. 2009 Jul 15;15:4529. doi: 10.1158/1078-0432.CCR-09-1363.
Abstract
摘要
相似文献
1
An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.
Clin Cancer Res. 2009 Jul 15;15:4529. doi: 10.1158/1078-0432.CCR-09-1363.
2
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6.
3
FDA requirements for nonclinical testing of contraceptive steroids.
Contraception. 1992 Dec;46(6):499-509. doi: 10.1016/0010-7824(92)90114-9.
4
To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
BMJ Open. 2019 Nov 25;9(11):e028677. doi: 10.1136/bmjopen-2018-028677.
5
A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
Eur J Clin Pharmacol. 2018 Jun;74(6):811-818. doi: 10.1007/s00228-018-2431-7. Epub 2018 Feb 22.
6
Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
BMC Health Serv Res. 2013 Jan 22;13:27. doi: 10.1186/1472-6963-13-27.
7
Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
JAMA Intern Med. 2023 Apr 1;183(4):290-297. doi: 10.1001/jamainternmed.2022.6787.
8
Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):709-15. doi: 10.1002/pds.3793. Epub 2015 May 27.
9
Regulatory review of novel therapeutics--comparison of three regulatory agencies.
N Engl J Med. 2012 Jun 14;366(24):2284-93. doi: 10.1056/NEJMsa1200223. Epub 2012 May 16.
10
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
Clin Pharmacol Ther. 2020 Jan;107(1):195-202. doi: 10.1002/cpt.1565. Epub 2019 Aug 14.
引用本文的文献
1
Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.
J Transl Med. 2024 Jul 3;22(1):621. doi: 10.1186/s12967-024-05428-9.
2
Inhibition of Metastasis by Polypyridyl Ru(II) Complexes through Modification of Cancer Cell Adhesion - Functional and Molecular Studies.
J Med Chem. 2022 Aug 11;65(15):10459-10470. doi: 10.1021/acs.jmedchem.2c00580. Epub 2022 Jul 27.
3
Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.
Int J Mol Sci. 2021 Jun 13;22(12):6336. doi: 10.3390/ijms22126336.
4
A spontaneously metastatic model of bladder cancer: imaging characterization.
J Transl Med. 2019 Dec 19;17(1):425. doi: 10.1186/s12967-019-02177-y.
5
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.
Clin Exp Metastasis. 2018 Apr;35(4):285-308. doi: 10.1007/s10585-018-9906-x. Epub 2018 Jun 8.
6
Pragmatic medicine in solid cancer: a translational alternative to precision medicine.
Onco Targets Ther. 2016 Apr 5;9:1839-55. doi: 10.2147/OTT.S103832. eCollection 2016.
7
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.
Cell Commun Signal. 2015 May 15;13:26. doi: 10.1186/s12964-015-0106-x.
8
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.
EMBO Mol Med. 2014 Dec;6(12):1561-76. doi: 10.15252/emmm.201403989.
9
Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy.
J Vis Exp. 2014 Apr 29(86):51485. doi: 10.3791/51485.
10
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Cancer Res. 2013 May 1;73(9):2743-8. doi: 10.1158/0008-5472.CAN-12-4183. Epub 2013 Apr 22.
本文引用的文献
1
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021.
2
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.
3
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.
Int J Oncol. 2008 Dec;33(6):1281-9.
4
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
Cancer Lett. 2009 Feb 18;274(2):271-8. doi: 10.1016/j.canlet.2008.09.026. Epub 2008 Nov 4.
5
Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma.
Clin Exp Metastasis. 2008;25(8):855-64. doi: 10.1007/s10585-008-9201-3. Epub 2008 Sep 3.
6
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.
Mol Cancer Ther. 2008 Aug;7(8):2272-9. doi: 10.1158/1535-7163.MCT-08-0182. Epub 2008 Aug 6.
7
Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.
BMC Cancer. 2008 Feb 8;8:47. doi: 10.1186/1471-2407-8-47.
8
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
J Clin Invest. 2007 May;117(5):1305-13. doi: 10.1172/JCI30740. Epub 2007 Apr 5.
9
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Cancer Res. 2007 Mar 1;67(5):2187-96. doi: 10.1158/0008-5472.CAN-06-3281.
10
Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells.
Clin Cancer Res. 2007 Jan 1;13(1):59-67. doi: 10.1158/1078-0432.CCR-06-1559.
Zotero 插件